Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 200Breast Neoplasms 124Carcinoma, Non-Small-Cell Lung 121Glioblastoma 93Neoplasms 75Ovarian Neoplasms 72Rectal Neoplasms 61Brain Neoplasms 59Lung Neoplasms 56Colonic Neoplasms 55Neoplasm Metastasis 51Glioma 49Carcinoma, Renal Cell 46Fallopian Tube Neoplasms 38Gliosarcoma 35Pancreatic Neoplasms 31Carcinoma, Hepatocellular 28Melanoma 26Adenocarcinoma of Lung 24Astrocytoma 21Stomach Neoplasms 20Uterine Cervical Neoplasms 16Recurrence 16Prostatic Neoplasms 16Liver Neoplasms 16Adenocarcinoma, Bronchiolo-Alveolar 16Esophageal Neoplasms 15Adenocarcinoma 15Carcinoma, Ovarian Epithelial 14Kidney Neoplasms 13

Interventions

carotuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adult Solid Tumor × Bevacizumab × Clear all
NCT01332721 2018-12-05

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Tracon Pharmaceuticals Inc.

Phase 1 Completed
38 enrolled 8 charts
Other solid neoplasm

Adult Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡